Furoquinolinediones as inhibitors of TDP2

A compound or pharmaceutically acceptable salt thereof of Formula I:

• wherein
• X1 is N or CR5;
• X2 is N or CR6;
• and
• at least one of X1 or X2 is N;
• R1 is hydroxyl or C1-C6alkoxy, where one or more methylene units in the alkoxy portion of R1 is optionally and independently replaced with —O— or —N(R7)—, and R1 other than hydroxyl is substituted by 0-3 substituents independently chosen at each occurrence from halogen, hydroxyl, cyano, ═N, ═NOR7, —CO2H, —(CO)—O—C1-C6alkyl, —C(O)NR7R8, and —W—P(O)YR9ZR10;
• Y1 is O, NH, or S;
• Y2 is N or C—R2;
• R2 is halogen, C1-C6alykyl, C1-C6haloalkyl, C1-C6haloalkoxy, —(C0-C6alkyl)cycloalkyl, —(C0-C6alkyl)NR7R8, or phenyl, each R2 other than halogen being substituted with 0 to 3 groups chosen independently at each occurrence from halogen, C1-C6haloalkyl, and C1-C6haloalkoxy;
• or
• R2 is a group -J-Q, where J is a 1 to 4 carbon alkylene linker in which any —CH2— group is optionally replaced by —C(O)O—, —C(O)NH—, —C(O)NR11, or —C(O)—;
• Q is C1-C6alkyl, C1-C6alkylamino, aryl, or heteroaryl, each of which is unsubstituted or substituted with one or more groups independently chosen from halogen, hydroxyl, amino, cyano, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy;
• W, Y, and Z are independently at each occurrence a bond or O;
• R3, R4, R5, and R6, are chosen independently at each occurrence from hydrogen, halogen, cyano, amino, C1-C6alkyl, —(C0-C6alkyl)cycloalkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy;
• R7, R1, R9 and R10 are chosen independently at each occurrence from hydrogen, C1-C6alkyl, C2-C6alkenyl, —(C0-C6alkyl)cycloalkyl, and C1-C6haloalkyl, and any R7 and R8 bound to the same nitrogen atom may be taken together to form a 4- to 7-membered heterocyloalkyl group substituted with 0 to 2 substituents chosen from hydroxyl, halogen, C1-C4alkyl, C1-C4alkoxy, and C2-C4alkanoyl;
• and
• R11 is C1-C6alkyl or C1-C6alkylamino-.